View More Recent Stories

Mar 17, 2025 08:13AM Ultragenyx Pharma (RARE) PT Lowered to $115 at Piper Sandler 'Ahead of Near-Term Value Inflection'

Feb 26, 2025 09:10AM Cantor Fitzgerald Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

Feb 19, 2025 07:13AM H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Feb 18, 2025 08:07AM Ultragenyx Pharma (RARE) Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A

Feb 18, 2025 06:52AM Ultragenyx Pharma (RARE) PT Raised to $136 at Canaccord Genuity

Feb 14, 2025 07:16AM Cantor Fitzgerald Reiterates Overweight Rating on Ultragenyx Pharma (RARE)

Feb 14, 2025 06:57AM Goldman Sachs Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Feb 13, 2025 08:55PM Truist Securities Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Feb 13, 2025 04:50PM Ultragenyx Pharma (RARE) Misses Q4 EPS by 5c; offers guidance

Feb 5, 2025 08:00AM Ultragenyx Pharma (RARE) Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with San

Jan 13, 2025 05:22AM Goldman Sachs on Ultragenyx Pharma (RARE): 'we remain constructive'

Jan 8, 2025 08:14AM RBC Capital on Ultragenyx Pharma (RARE): 'We Believe RARE Has A Drug For Osteogenesis Imperfecta'

Dec 24, 2024 06:51AM H.C. Wainwright Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025

Dec 20, 2024 09:30AM Buy this biotech stock for 2025: Jefferies

Dec 19, 2024 08:02AM Ultragenyx Pharma (RARE) Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A

Dec 17, 2024 06:17AM BofA Updates Endeavor List

Dec 5, 2024 03:13PM Ultragenyx Pharma (RARE) 1K contracts of July 60 calls trade

Nov 6, 2024 06:44AM Ultragenyx Pharma (RARE) PT Raised to $95 at H.C. Wainwright

Nov 6, 2024 05:58AM Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

Nov 5, 2024 04:14PM Ultragenyx Pharma (RARE) Tops Q3 EPS by 8c, provides guidance

Oct 7, 2024 08:03AM Ultragenyx Pharma (RARE) Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

Oct 4, 2024 05:54AM Leerink Partners Reiterates Outperform Rating on Ultragenyx Pharma (RARE)

Oct 3, 2024 04:31PM Ultragenyx Pharma (RARE) Provides Update on Stage 1 Cohorts in Phase 1/2/3 Cyprus2+ Study

Oct 1, 2024 07:51AM TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Sep 30, 2024 08:30AM JPMorgan refreshed its U.S. Analyst Focus List, adding these six stocks

Sep 25, 2024 11:00AM JPM just refreshed its US Analyst Focus List, adding these 5 stocks

Sep 17, 2024 02:00PM JPMorgan refreshed its U.S. Analyst Focus List and added these four names

Aug 1, 2024 05:34PM Ultragenyx Pharma (RARE) Tops Q2 EPS by 14c; offers guidance

Jul 30, 2024 07:17AM RBC's biotech survey shows investors more bearish vs. last time

Jul 17, 2024 04:05PM Ultragenyx Pharma (RARE) Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102

Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview

Jun 17, 2024 02:17PM TD Cowen Reiterates Buy Rating on Ultragenyx Pharma (RARE)

Jun 12, 2024 04:45PM After-hours movers: Broadcom, Dave & Buster's, Oxford Industries, and more

Jun 12, 2024 04:05PM Ultragenyx Pharma (RARE) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 12, 2024 04:00PM Ultragenyx Pharma (RARE) to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A

Jun 12, 2024 08:12AM Ultragenyx Pharma (RARE), Mereo BioPharma (MREO) Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) i

View More Recent Stories